NF-κB-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
05 2019
Historique:
received: 04 08 2018
accepted: 05 01 2019
revised: 09 12 2018
pubmed: 1 2 2019
medline: 12 10 2019
entrez: 1 2 2019
Statut: ppublish

Résumé

We previously showed that NADPH oxidase organizer 1 (Noxo1), a component of NADPH oxidase 1 (NOX1), is a TNF-α-induced tumor-promoting factor in gastric tumorigenesis. However, the mechanism of NOX1-induced reactive oxygen species (ROS) signaling for the gastric tumorigenesis has not been understood. Here, we showed that expression of NOX1 complex components, including Noxo1, but not other NOX family members was significantly upregulated in both mouse models for gastritis and gastric tumors, which was associated with increased ROS levels. We also found that NF-κB directly regulated NOXO1 expression in TNF-α-stimulated gastric cancer cells, suggesting that inflammation induces NOX1 complex activation through TNF-α/NF-κB pathway. Notably, in situ hybridization indicated that Noxo1 mRNA was detected in proliferating cells of gastritis and gastric tumors, and pharmacological inhibition of NOX activity significantly suppressed the proliferation of MKN45 gastric cancer cells and gastric hyperplasia of K19-C2mE mice. These results suggest that NOX1/ROS signaling has an important role in increased proliferation of stomach epithelial cells in the inflamed mucosa. Moreover, we found that expression of SOX2, a marker of gastric epithelial stem cells, was increased by NOX1/ROS signaling. Furthermore, disruption of Noxo1 in K19-C2mE mice significantly suppressed gastritis-associated metaplastic hyperplasia, a potent preneoplastic lesion, which was associated with decreased number of SOX2-positive cells. These results indicate that inflammation-induced Noxo1 expression is responsible for development of metaplastic hyperplasia in the stomach through an increase in SOX2-expressing undifferentiated epithelial cells. Therefore, inhibition of the NOX1/ROS signaling pathway is a possible strategy for prevention and therapy for gastric cancer development.

Identifiants

pubmed: 30700829
doi: 10.1038/s41388-019-0702-0
pii: 10.1038/s41388-019-0702-0
pmc: PMC6756228
doi:

Substances chimiques

NF-kappa B 0
Reactive Oxygen Species 0
SOXB1 Transcription Factors 0
Sox2 protein, mouse 0
Tumor Necrosis Factor-alpha 0
NADPH Oxidase 1 EC 1.6.3.-
NOX1 protein, mouse EC 1.6.3.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4250-4263

Références

Gastroenterology. 2006 Oct;131(4):1086-95
pubmed: 17030179
Oncogene. 2014 May 8;33(19):2540-6
pubmed: 23728346
Cell Mol Gastroenterol Hepatol. 2017 Feb 20;3(3):316-322
pubmed: 28462373
Gastroenterology. 2015 Oct;149(5):1153-1162.e3
pubmed: 26073375
Nature. 2014 Sep 11;513(7517):202-9
pubmed: 25079317
Cancer Res. 1997 Apr 1;57(7):1276-80
pubmed: 9102213
Mol Cells. 2010 Jul;30(1):1-12
pubmed: 20652490
Cancer Prev Res (Phila). 2016 Mar;9(3):253-63
pubmed: 26888865
Cell Stem Cell. 2011 Oct 4;9(4):317-29
pubmed: 21982232
Cell Death Differ. 2014 Aug;21(8):1185-97
pubmed: 24632950
Lancet. 2016 Nov 26;388(10060):2654-2664
pubmed: 27156933
Trends Mol Med. 2007 Nov;13(11):460-9
pubmed: 18029230
Nat Rev Cancer. 2010 Jun;10(6):403-14
pubmed: 20495574
Nat Cell Biol. 2014 Dec;16(12):1238-48
pubmed: 25362351
Nat Rev Drug Discov. 2013 Dec;12(12):931-47
pubmed: 24287781
Am J Physiol Gastrointest Liver Physiol. 2006 Dec;291(6):G999-1004
pubmed: 17090722
Cell Res. 2011 Jan;21(1):103-15
pubmed: 21187859
Clin Cancer Res. 2012 Nov 1;18(21):5992-6000
pubmed: 22977193
Nat Rev Cancer. 2012 Sep;12(9):627-37
pubmed: 22918415
Cancer Res. 2016 Feb 15;76(4):855-65
pubmed: 26781991
Cell Stem Cell. 2013 Jun 6;12(6):761-73
pubmed: 23665120
Cancer Res. 2005 Oct 15;65(20):9147-51
pubmed: 16230370
Oncogene. 2010 Feb 11;29(6):781-8
pubmed: 19946329
FASEB J. 2013 Apr;27(4):1733-48
pubmed: 23322165
Gastroenterology. 2003 Aug;125(2):364-71
pubmed: 12891537
Clin Sci (Lond). 2015 Jun;128(12):863-75
pubmed: 25818486
Cancer Sci. 2009 Aug;100(8):1382-8
pubmed: 19493276
EMBO J. 2004 Apr 7;23(7):1669-78
pubmed: 15014433
Oncogene. 2014 Jul 17;33(29):3820-9
pubmed: 23975421
Gastroenterology. 2003 May;124(5):1193-201
pubmed: 12730860
Cell. 2013 Jan 17;152(1-2):25-38
pubmed: 23273993
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Cancer Sci. 2011 Apr;102(4):713-9
pubmed: 21205091
Cell Rep. 2016 Aug 16;16(7):1929-41
pubmed: 27498859
Oncogene. 2008 Aug 21;27(36):4921-32
pubmed: 18454176
Cancer Cell. 2012 Oct 16;22(4):466-78
pubmed: 23079657
Cancer Sci. 2016 Apr;107(4):391-7
pubmed: 27079437
Cell Stem Cell. 2010 Jan 8;6(1):25-36
pubmed: 20085740

Auteurs

Kanae Echizen (K)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.
AMED-CREST, AMED, Japan Agency for Medical Research and Development, Tokyo, 100-0004, Japan.

Keigo Horiuchi (K)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.

Yayoi Aoki (Y)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.

Yoichi Yamada (Y)

Faculty of Electrical and Computer Engineering, Institute of Science and Engineering, Kanazawa University, 920-1192, Kanazawa, Japan.

Toshinari Minamoto (T)

Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, 920-8640, Japan.

Hiroko Oshima (H)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan.
WPI-Nano Life Science Institute, Kanazawa University, Kanazawa, 920-1192, Japan.

Masanobu Oshima (M)

Division of Genetics, Cancer Research Institute, Kanazawa University, Kanazawa, 920-1192, Japan. oshimam@staff.kanazawa-u.ac.jp.
AMED-CREST, AMED, Japan Agency for Medical Research and Development, Tokyo, 100-0004, Japan. oshimam@staff.kanazawa-u.ac.jp.
WPI-Nano Life Science Institute, Kanazawa University, Kanazawa, 920-1192, Japan. oshimam@staff.kanazawa-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH